Rho‐kinase and myosin II activities are required for cell type and environment specific migration
- 21 January 2005
- journal article
- Published by Wiley in Genes to Cells
- Vol. 10 (2) , 107-117
Abstract
Cell migration is important in the development of atherosclerotic lesions. Macrophages and smooth muscle cells migrate into the subendothelial space of arteries, leading to plaque formation. Long‐term inhibition of the activity of Rho‐kinase induces a regression of atherosclerotic coronary lesions, probably by preventing migration of macrophages and smooth muscle cells. Previous reports concerning the effect of Rho‐kinase inhibitors on cell migration are contradictory, however. We examined here the cell type specificity of Rho‐kinase inhibitors and found that migration of endothelial cells, macrophages, and smooth muscle cells was inhibited by treatment with Rho‐kinase inhibitors in a dose‐dependent fashion in a three‐dimensional migration assay, whereas that of fibroblasts and epithelial cells was not inhibited. Myosin II inhibitor prevented cell migration in a manner similar to Rho‐kinase inhibitors. In contrast, in a two‐dimensional migration assay, cell migration was not inhibited by Rho‐kinase or myosin II inhibitors for any of the cell types examined. Taken together, these results indicate that Rho‐kinase inhibitors suppress migration of specific cell types under specific conditions through the regulation of myosin II activity. Our findings suggest that Rho‐kinase is the therapeutic target of atherosclerosis accompanied with invasion by leukocytes and smooth muscle cells.Keywords
This publication has 42 references indexed in Scilit:
- Long-Term Treatment With a Specific Rho-Kinase Inhibitor Suppresses Cardiac Allograft Vasculopathy in MiceCirculation Research, 2004
- Cell Migration: Integrating Signals from Front to BackScience, 2003
- Rho-Associated Protein Kinase Contributes to Early Atherosclerotic Lesion Formation in MiceCirculation Research, 2003
- Dissecting Temporal and Spatial Control of Cytokinesis with a Myosin II InhibitorScience, 2003
- Microtubule involvement in NIH 3T3 Golgi and MTOC polarity establishmentJournal of Cell Science, 2003
- Inflammation in atherosclerosisNature, 2002
- Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertensionThe FASEB Journal, 2001
- Identification of IQGAP as a Putative Target for the Small GTPases, Cdc42 and Rac1Journal of Biological Chemistry, 1996
- Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor.Journal of Clinical Investigation, 1996
- Heparin-like Molecules on the Cell Surface Potentiate Binding of Diphtheria Toxin to the Diphtheria Toxin Receptor/Membrane-anchored Heparin-binding Epidermal Growth Factor-like Growth FactorJournal of Biological Chemistry, 1995